AI Science Tracker

Tianjin Medical University

1 discovery from 2025

Discoveries

CHANCE uses tumor genomes to prioritize non-cancer drugs with activity in patient-derived cancer cells

CHANCE, a supervised machine-learning model integrating patient-specific coding and non-coding mutations with drug and protein-interaction information, screened 5,197 TCGA/ICGC tumors against 923 FDA-approved non-oncology drugs. For ex-vivo validation, the investigators sequenced tumor cells from seven patients with pancreatic or esophageal cancer and tested CHANCE-prioritized drugs; at least one predicted non-oncology drug showed anticancer activity in tumor cells from five of the seven patients. This is patient-specific cell-assay validation, not a treatment-response study in patients.

Technology: CHANCE, a supervised gradient-boosted-tree model integrating coding/non-coding variants, protein–protein interaction networks, drug targets and drug-response data

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: For ex-vivo validation, the investigators sequenced tumor cells from seven patients with pancreatic or esophageal cancer and tested CHANCE-prioritized drugs; at least one predicted non-oncology drug showed anticancer activity in tumor cells from five of the seven patients.
  • Still unknown: Only seven patient-derived samples were tested, from pancreatic or esophageal cancers; at least one prioritized non-oncology drug showed activity in five. This was an ex-vivo drug-sensitivity assay, not clinical treatment, and the study does not establish efficacy, safety, dosing or patient benefit. The 5,197-tumor/923-drug screen is computational prediction; only the small patient-derived subset had experimental validation. Drug-response predictions may include drugs represented in training, as the article notes 149 of 923 screened drugs were in the training data.
  • AI role: Trained on drug-sensitivity measurements from 318 cancer cell lines across 647 drugs, CHANCE maps each patient tumor’s whole-genome mutations to drug-target/pathway features and ranks non-oncology drugs by predicted patient-specific anticancer activity. Investigators used these predictions to select drugs for ex-vivo testing in tumor cells from seven patients; the reported five-patient activity result tests the model’s personalized prioritization.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11794852/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: at percentile 79 of works of the same type, year and subfield (OpenAlex work metrics, 5 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.